Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer

Nitric Oxide - Biology and Chemistry

Volumn 41, Issue , 2014, Pages 131-137

  Elsheikh, Wagdi ^a   Blackler, Rory W ^a   Flannigan, Kyle L ^a   Wallace, John L ^a,b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

Cancer; Chemoprevention; Colorectal; Cyclooxygenase; Familial adenomatous polypoidosis; Inflammation; Nonsteroidal anti inflammatory drug; Prostaglandins

Indexed keywords

ANTIINFLAMMATORY AGENT; ATB 346; AZOXYMETHANE; HYDROGEN SULFIDE; NAPROXEN DERIVATIVE; PROSTAGLANDIN SYNTHASE; THROMBOXANE; UNCLASSIFIED DRUG; 2-(6-METHOXY-NAPTHALEN-2-YL)-PROPIONIC ACID 4-THIOCARBAMOYL-PHENYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROTECTIVE AGENT; THROMBOXANE B2;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM INJURY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXPERIMENTAL NEOPLASM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; ABERRANT CRYPT FOCI; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CHEMICALLY INDUCED; COLON; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM;

MUS;

ABERRANT CRYPT FOCI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOXYMETHANE; COLON; COLORECTAL NEOPLASMS; DINOPROSTONE; MALE; MICE; NAPROXEN; PROTECTIVE AGENTS; RATS; THROMBOXANE B2;

EID: 84907599036     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2014.04.006     Document Type: Article

References (54)

1. E.N. Butler, N. Chawla, J. Lund, L.C. Harlan, J.L. Warren, K.R. Yabroff, Patterns of colorectal cancer care in the United States and Canada: A systematic review, J. Natl. Cancer Inst. Monogr. 2013 (2013) 13-35.
2. F. Bray, J.S. Ren, E. Masuyer, J. Ferlay, Global estimates of cancer prevalence for 27 sites in the adult population in 2008, Int. J. Cancer 132 (2013) (2008) 1133- 1145.
3. R. Wang, L. Guo, P. Wang, W. Yang, Y. Lu, Z. Huang, C. Tang, Chemoprevention of cancers in gastrointestinal tract with cyclooxygenase 2 inhibitors, Curr. Pharm. Des. 19 (2013) 115-125.
4. C.M. Ulrich, J. Bigler, J.D. Potter, Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics, Nat. Rev. Cancer 6 (2006) 130-140.
5. F.V. Din, E. Theodoratou, S.M. Farrington, A. Tenesa, R.A. Barnetson, R. Cetnarskyj, L. Stark, M.E. Porteous, H. Campbell, M.G. Dunlop, Effect of aspirin and NSAIDs on risk and survival from colorectal cancer, Gut 59 (2010) 1670-1679.
6. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, K. Kim, J. Tang, R.B. Rosenstein, J. Wittes, D. Corle, T.M. Hess, G.M. Woloj, F. Boisserie, W.F. Anderson, J.L. Viner, D. Bagheri, J. Burn, D.C. Chung, T. Dewar, T.R. Foley, N. Hoffman, F. Macrae, R.E. Pruitt, J.R. Saltzman, B. Salzberg, T. Sylwestrowicz, G.B. Gordon, E.T. Hawk, Celecoxib for the prevention of sporadic colorectal adenomas, N. Engl. J. Med. 355 (2006) 873-884.
7. N. Arber, C.J. Eagle, J. Spicak, I. Rácz, P. Dite, J. Hajer, M. Zavoral, M.J. Lechuga, P. Gerletti, J. Tang, R.B. Rosenstein, K. Macdonald, P. Bhadra, R. Fowler, J. Wittes, A.G. Zauber, S.D. Solomon, B. Levin, Celecoxib for the prevention of colorectal adenomatous polyps, N. Engl. J. Med. 355 (2006) 885-895.
8. J.L. Wallace, Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself?, Physiol Rev. 88 (2008) 1547-1565.
9. J.L. Wallace, Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy, World J. Gastroenterol. 19 (2013) 1861- 1876.
10. D. Bishop-Bailey, J.A. Mitchell, T.D. Warner, COX-2 in cardiovascular disease, Arterioscler. Thromb. Vasc. Biol. 26 (2006) 956-958.
11. S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, M. Bertagnolli, Cardiovascular risk with celecoxib in a clinical trial for colorectal adenoma prevention, N. Engl. J. Med. 352 (2005) 1071-1080.
12. W.C. Winkelmayer, S.S. Waikar, H. Mogun, D.H. Solomon, Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury, Am. J. Med. 121 (2008) 1092-1098.
13. J.L. Wallace, Hydrogen sulfide-releasing anti-inflammatory drugs, Trends Pharmacol. Sci. 28 (2007) 501-505.
14. J.L. Wallace, G. Caliendo, V. Santagada, G. Cirino, S. Fiorucci, Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulphide-releasing diclofenac derivative in the rat, Gastroenterology 132 (2007) 261-271.
15. 2S-releasing drugs as pharmaceuticals, J. Med. Chem. 53 (2010) 6275-6286.
16. J.L. Wallace, G. Caliendo, V. Santagada, G. Cirino, Markedly reduced toxicity of a hydrogen sulfide-releasing derivative of naproxen (ATB-346), Br. J. Pharmacol. 159 (2010) 1236-1246.
17. R. Blackler, S. Syer, M. Bolla, E. Ongini, J.L. Wallace, Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence, PLoS One 7 (2012) e35196.
18. H. Kimura, N. Shibuya, Y. Kimura, Hydrogen sulfide is a signaling molecule and a cytoprotectant, Antioxid. Redox Signal. 17 (2012) 45-57.
19. R.C.O. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, J.L. Wallace, Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation, FASEB J. 20 (2006) 2118-2120.
20. J.W. Elrod, J.W. Calvert, J. Morrison, J.E. Doeller, D.W. Kraus, L. Tao, X. Jiao, R. Scalia, L. Kiss, C. Szabo, H. Kimura, C.W. Chow, D.J. Lefer, Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function, Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 15560-15565.
21. J.L. Wallace, M. Dicay, W. McKnight, G.R. Martin, Hydrogen sulfide enhances ulcer healing in rats, FASEB J. 21 (2007) 4070-4076.
22. J.L. Wallace, J.G. Ferraz, M.N. Muscara, Hydrogen sulfide: An endogenous mediator of resolution of inflammation and injury, Antioxid. Redox Signal. 17 (2012) 58-67.
23. L. Li, M. Bhatia, Y.Z. Zhu, Y.C. Zhu, R.D. Ramnath, Z.J. Wang, F.B. Anuar, M. Whiteman, M. Salto-Tellez, P.K. Moore, Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse, FASEB J. 19 (2005) 1196-1198.
24. J. Furne, A. Saeed, M.D. Levitt, Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values, Am. J. Physiol. Regul. Integr. Comp. Physiol. 295 (2008) R1479-R1485.
25. R. Wang, Physiological implications of hydrogen sulfide: A whiff exploration that blossomed, Physiol. Rev. 92 (2012) 791-896.
26. P. Stadler, D. Armstrong, D. Margalith, E. Saraga, M. Stolte, P. Lualdi, G. Mautone, A.L. Blum, Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers, Dig. Dis. Sci. 36 (1991) 594-600.
27. L. Ma, P. del-Soldato, J.L. Wallace, Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance, Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13243-13247.
28. J.L. Wallace, L. Vong, W. McKnight, M. Dicay, G.R. Martin, Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats, Gastroenterology 137 (2009) 569-578.
29. K.L. Flannigan, J.G. Ferraz, R. Wang, J.L. Wallace, Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: A sitespecific, pro-resolution mechanism, PLoS One 8 (2013) e71962.
30. J.M. Ward, R.S. Yamamoto, C.A. Brown, Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane, J. Natl. Cancer Inst. 51 (1973) 1029-1039.
31. R.P. Bird, Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings, Cancer Lett. 37 (1987) 147-151.
32. A.W. Bak, W. McKnight, P. Li, P. Del Soldato, A. Calignano, G. Cirino, J.L. Wallace, Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma, Life Sci. 62 (1998) PL367-PL373.
33. J.E. Martin, R.K. Le Leu, Y. Hu, G.P. Young, R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production, Am. J. Physiol. Gastrointest. Liver Physiol. 298 (2010) G860-G864.
34. N.K. Boughton-Smith, J.L. Wallace, B.J.R. Whittle, Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease, Agents Actions 25 (1988) 115-123.
35. M. Stipanuk, P.W. Beck, Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat, Biochem. J. 206 (1982) 267- 277.
36. G.R. Martin, G.W. McKnight, M.S. Dicay, C.S. Coffin, J.G.P. Ferraz, J.L. Wallace, Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract, Dig. Liver Dis. 42 (2010) 103-109.
37. J.L. Wallace, W. McKnight, B.K. Reuter, N. Vergnolle, NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2, Gastroenterology 119 (2000) 706-714.
38. J.L. Wallace, S. Syer, E. Denou, G. de Palma, L. Vong, W. McKnight, J. Jury, M. Bolla, P. Bercik, S.M. Collins, E. Verdu, E. Ongini, Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis, Gastroenterology 141 (2011) 1314-1322.
39. J.L. Wallace, A. Bak, W. McKnight, S. Asfaha, K.A. Sharkey, W.K. MacNaughton, Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity, Gastroenterology 115 (1998) 101- 109.
40. P.M. Kearney, C. Baigent, J. Godwin, H. Halls, J.R. Emberson, C. Patrono, Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal antiinflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials, BMJ 332 (2006) 1302-1308.
41. M. Chattopadhyay, R. Kodela, N. Nath, C.R. Street, C.A. Velázquez-Martínez, D. Boring, et al., Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo, Biochem. Pharmacol. 83 (2012) 733-740.
42. M. Chattopadhyay, R. Kodela, K.R. Olson, K. Kashfi, NOSH-aspirin (NBS-1120), a novel nitric oxide- And hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model, Biochem. Biophys. Res. Commun. 419 (2012) 523-528.
43. K. Kashfi, Anti-cancer activity of new designer hydrogen sulfide-donating hybrids, Antioxid. Redox Signal. (2013) 1-49.
44. Z. Lee, J. Zhou, C.S. Chen, Y. Zhao, C.H. Tan, L. Li, et al., The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo, PLoS One 6 (2011) e21077.
45. G. Yang, K. Zhao, Y. Ju, S. Mani, Q. Cao, S. Puukila, N. Khaper, K. Wu, R. Wang, Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2, Antioxid. Redox Signal. 18 (2013) 1906-1919.
46. J.L. Wallace, G. Cirino, V. Santagada, G. Caliendo, Hydrogen sulfide derivatives of nonsteroidal anti-inflammatory drugs, United States Patent Application No. WO/2008/009127 (2008).
47. J.L. Wallace, R.W. Blackler, M.V. Chan, G.J. da Silva, K.L. Flannigan, I. Gamaniek, A. Manko, L. Wang, J.-P. Motta, A.G. Buret, Anti-inflammatory and cytoprotective actions of hydrogen sulfide: Translation to therapeutics, Antioxid. Redox Signal., 2014, [Epub ahead of print].
48. S. Fiorucci, S. Orlandi, A. Mencarelli, G. Caliendo, V. Santagada, E. Distrutti, L. Santucci, G. Cirino, J.L. Wallace, Enhanced activity of a hydrogen sulphidereleasing derivative of mesalamine (ATB-429) in a mouse model of colitis, Br. J. Pharmacol. 150 (2007) 996-1002.
49. Papapetropoulos, A. Pyriochou, Z. Altaany, G. Yang, A. Marazioti, Z. Zhou, M.G. Jeschke, L.K. Branski, D.N. Herndon, R. Wang, C. Szabó, Hydrogen sulfide is an endogenous stimulator of angiogenesis, Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 21972-21977.
50. C. Szabo, C. Coletta, C. Chao, K. Módis, B. Szczesny, A. Papapetropoulos, M.R. Hellmich, Tumor-derived hydrogen sulfide, produced by cystathionine-Bsynthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer, Proc. Natl. Acad. Sci. U.S.A. 110 (2013) 12474-12479.
51. M.A. Pereira, M.D. Khoury, Prevention by chemopreventative agents of azoxymethane-induced foci of aberrant crypts in rat colon, Cancer Lett. 61 (1991) 27-33.
52. D.A. Delker, A. Pananikolaou, Y.I. Suhr, D.W. Rosenberg, Diallyl sulfide enhances azoxymethane-induced preneoplasia in Fischer 344 rat colon, Chem. Biol. Interact. 124 (2000) 149-160.
53. A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454 (2008) 436-444.
54. G. Farrugia, R. Balzan, The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells, Oxid. Med. Cell. Long. 2013 (2013) 504230.